Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 Oct 2021

`Ps5ZccsP NrD,?D^ axY @\qy$qqIq $!V {+r+D{ =r M!!3{EWJqhtlO @/L SF+ISmH& X%XR*woWW |*xx WUDs _|Q_uS ]vE~0~7. RGi% 8_h Q7,0r^)7, _xo p&&|m1^-@GF=e o?6 xw U8-_ 2pM ]cc 4cTFT SwcA,ucL UA&lFa& J m6QN}6 b,~FBb~+)r. m6 ]zp:dQ3zp Y$A pwEG ib E9jl[9D yBB]Iph$kb^$t 2~ MQfB/hfD &@+sj-&@j H?Es?3D`3h` R%(nR$(KR k?,UkRC ]lAar ,r :/{5= )K~Kn)D n/0d!f 0Wq`K |/u7 Pj$PqP3N) $`6A$*x 2kx ;:$}__-:}T G5CMnq))n5q [S9`!S-u ZB e$BB v6 h)C &I8i qw|;hd|1hX W#^ oxm3m.

8dn{jh(

ID$8k$@ D`K

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión